A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

To evaluate the efficacy of Tapinarof cream, 1% in subjects with atopic dermatitis (AD).

Sponsor(s)
Dermavant Sciences, Inc.
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Request Information
Address
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.